Coronbio-Tech-B (06990.HK) announced that on June 17th (today), it received the clinical trial notice of SKB518, an innovative drug injection developed by the company, approved by the drug evaluation center of the National Pharmaceutical Administration.
SKB518, an injection, is an innovative antibody drug developed by the company using the OptiDC platform technology based on the characteristics of target biology. It has shown good efficacy and safety in preclinical studies and is intended for the treatment of advanced solid tumors.